Growth hormone deficiency pathophysiology

Growth hormone deficiency Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Growth hormone deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Growth hormone deficiency pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Growth hormone deficiency pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Growth hormone deficiency pathophysiology
CDC on Growth hormone deficiency pathophysiology
Growth hormone deficiency pathophysiology in the news
Blogs on Growth hormone deficiency pathophysiology
Directions to Hospitals Treating Growth hormone deficiency
Risk calculators and risk factors for Growth hormone deficiency pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Pathophysiology

• The somatotroph cells of the anterior pituitary gland produce growth hormone.
• They are regulated by two hypothalamic hormones; GH-releasing hormone (GHRH) stimulates and somatostatin inhibits them.
• GH deficiency results in alterations in the physiology of different systems of the body, manifesting as altered lipid metabolism, increased subcutaneous visceral fat, decreased muscle mass, decreased bone density, low exercise performance, and reduced quality of life.

Genetics

MOLECULAR GENETICS OF GROWTH HORMONE DEFICIENCY

30 percent of GHD is genetic [9,10].

The POU1F1 gene

is responsible for pituitary-specific transcription of genes for GH, prolactin, thyrotropin, and the growth hormone releasing hormone (GHRH) receptor [11,12].

PROP1 mutations result in failure to activate POU1F1/Pit1 gene expression and probably cause pituitary hypoplasia and/or familial multiple pituitary hormone deficiency [17]; paradoxical cystic hyperplasia of the pituitary also has been reported [18]. This is the most common known genetic cause of combined pituitary hormone deficiency [19,20].

GHRH receptor gene defects

Children with mutations in the GHRH receptor gene have undetectable GH release during standard provocative tests and after exogenous GHRH administration, but they respond to GH treatment.

Deletions and mutations of GH1 

GH1 is the gene encoding GH, located on chromosome 17. Gene deletions, frameshift mutations, and nonsense mutations of GH1 have been described as causes of familial GHD [25].

Syndrome of bioinactive GH

A diagnosis of the syndrome of bioinactive GH has been proposed for short children with a phenotype that resembles that of isolated GHD, with normal or slightly elevated basal GH levels in combination with low insulin-like growth factor I (IGF-I) concentrations that increase after treatment with exogenous GH. True molecular abnormalities involving a mutant GH molecule have rarely been reported [26,27]

Laron syndrome

It is caused by homozygous or compound heterozygous mutations in the growth hormone (GH) receptor gene; a variety of mutations have been identified, most of which affect the extracellular GH-binding region of the receptor [2-4].

GH receptor signal transduction 

a homozygous missense mutation in the gene encoding signal transducer and activator transcription 5B (STAT5B) which is essential for normal signaling of the GH receptor [15-18].

IGF-I gene mutations 

Mutations in the gene encoding IGF-I cause a unique syndrome of GHD  21-23

patients with IGF-I gene mutations have prenatal growth failure, microcephaly, significant neurocognitive deficits, sensorineural hearing loss 21

Defective stabilization of circulating IGF-I 

deficiency of acid-labile subunit (ALS) which is important for the stabilization of the IGF-I-IGFBP-3 complex, forming a three-part (ternary) complex in the circulation. [25,26].

IGF-I receptor mutations 

Mutations in the gene encoding the receptor for IGF-I have been reported in infants presenting with pre- and postnatal growth failure [27-30].

These mutations are thought to result in partial loss of function of the IGF-I receptor